Up-regulation of ICAM-1 expression on human dermal fibroblasts by IFN β in the presence of TNF-α  by Horikoshi, Takashi et al.
FEBS 15371 FEBS Letters 363 (1995) 141-144 
Up-regulation of ICAM- expression on human dermal fibroblasts by 
IFN-P in the presence of TNF-a 
Takashi Horikoshi”,*, Kyori Ezoeb, Hidemi Nakagawac, Hiroaki Eguchi”, Niro Hanadaa, 
Shuji Hamaokaa 
‘Department of Dermatology, School of Medicine. Sapporo Medical University, Sl, WI6, Chuoku, Sapporo 060, Japan 
bDepartment of Plastic Surgery, School of Medicine. Sapporo Medical University, SI. W16. Chuoku, Sapporo 060, Japan 
“Department of Dermatology, Faculty of Medicine. Tokyo University, Honngo 7-3-1, Bunkyoku, Tokyo 113, Japan 
Received 21 February 1995 
Abstract Unstimulated human fibroblasts show low or undetect- 
able ICAM- expression. Interferon-beta (IFN-P) at concentra- 
tions of 10,100, and 1000 IUlml in the presence of tumor necrosis 
factor-alpha (TNF-a) significantly increased the ICAM- ex- 
pression of fibroblasts in a dose-dependent manner. Treatment 
with IFN-P alone, however, did not up-regulate the ICAM- 
expression. Furthermore the attachment of peripheral blood 
mononuclear cells (PBMCs) to cytokine-treated fibroblasts was 
increased. This augmented attachment was partly inhibited by 
anti-ICAM- antibody. These results suggest that IFN-/3 and 
TNF-(I! may cooperatively modulate the attachment of PBMCs 
in the dermis. 
[13]. Interestingly, IFN-j? is produced by human dermal fibro- 
blasts [14] and its production is exponentially increased by a 
small amount of exogenously added IFN-p itself in vitro (un- 
published data). However, the effects of IFNs on the expression 
of cell adhesion molecules have not been fully elucidated yet in 
fibroblasts. We show here the significant up-regulation of 
TNF-a-induced ICAM- expression by IFN-b on dermal fi- 
broblasts. 
2. Materials and methods 
2.1. Cell culture methods 
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1. Introduction 
Intercellular adhesion molecule (ICAM)-l is a cell surface 
glycoprotein expressed in many cell lines [l-3]. It belongs to a 
member of the immunoglobulin superfamily [4] and can func- 
tion as an adhesive ligand for leukocyte function associated 
molecule (LFA)-1 [3,5]. The interaction between ICAM- and 
LFA-1 is thought to play an important role in immunologic and 
inflammatory responses such as leukocyte migration into der- 
mis and epidermis [6-S]. In vitro, unstimulated human fibro- 
blasts show low or undetectable ICAM- expression. It is 
known that the expression of ICAM- on fibroblasts can be 
up-regulated by cytokines such as tumor necrosis factor-alpha 
(TNF-a), interferon-gamma (IFN-y), interleukin-lbeta (IL- 
l/$, and IL-4 [2,9-111. However, as cytokines act simultane- 
ously in the vivo situation, it is necessary to clarify how these 
cytokines form a network in modulating the expression of 
ICAM-1. Both IL-4 and IFN-I/ stimulated the expression of 
ICAM- of fibroblasts and these cytokines display cooperative 
effects [ll]. Thus it is important to investigate how these cytok- 
ines interact with one another in modulating the expression of 
ICAM-1. 
Human dermal fibroblasts from surgically removed normal infant 
skins were isolated by explant outgrowth as previously described [15]. 
Cells were maintained in minimum essential medium (MEM) (Flow 
Laboratories) containing Earle’s salt supplemented with 10% heat- 
inactivated fetal calf serum (FCS) (Flow Laboratories), penicillin (100 
IU/ml) and streptomycin (100 ,@ml) (Gibco) in 5% CO, and 95% air 
at 37°C. Cells were detached from culture flasks by 0.05% trypsin/0.53 
mM EDTA (Gibco, Grand Island, NY) and subcultured at a 1: 3 split 
ratio. Five different strains were used between their 4th and 7th pas- 
sages for the experiments. 
2.2. Reagents 
The following reagents were used for experiments. Human fibroblast 
IFN-p was a kind gift from Toray (Tokyo, Japan); human recom- 
binant-TNF-cr from Dainippon pharmaceutical Co. (Osaka, Japan); 
anti-ICAM- monoclonal antibody (MoAb) and FITC-conjugated 
anti-ICAM- MoAb (CD54) (mouse IgGl) were purchased from 
Immunotech (USA). Fluorescein isothiocyanate (FITC)-conjugated 
mouse immunoglobulin (IgGl) was from Becton Dicknson. 
2.3. Flow cytometry 
Interferon was first characterized as an antiviral substance 
[12] and is believed to be an integral part of a cytokine network 
Fluorescence activated cell sorter (FACS) analysis was performed as 
previously described [15]. Human dermal fibroblasts were seeded in 25 
cm* flasks (Falcon) at a density of 104/cm2. 24 h after seeding, attached 
cells were treated with TNF-a and IFN-b either alone or in combina- 
tion at various concentrations for 48 h. Experiments were carried out 
using MEM containing low FCS (2%) to minimize the effect of serum 
on cytokines. Then, cells were detached from the dish by treatment with 
1 mM EDTA. Cells were rinsed twice with phosphate buffered saline 
(PBS) without Ca” and Mg’+ containing 0.1% sodium azide and 
stained with FITC-conjugated purified anti-ICAM- MoAb (mouse 
IgGl) at 4°C for 30 min. As a negative control, isotype matched FITC- 
conjugated mouse immunoglobulin was used. After rinsing three times 
with PBS, cells were fixed with 1% paraformaldehyde. Samples were 
analyzed using a FACScan (Becton Dickinson). Data of FACS were 
expressed as log mean fluorescence. 
*Corresponding author. Fax: (81) (11) 613-3739. 
2.4. Preparation of peripheral blood mononuclear cells (PBMCs) 
Abbreviations; IFN-B, interferon-beta; TNF-a, tumor necrosis factor- Whole blood from normal healthy donors was collected into syringes 
alpha; PBMCs, peripheral blood mononuclear cells; ICAM-1, intercel- containing heparin. Purified PBMCs were isolated by dextran sedimen- 
lular adhesion molecule-l; LFA-1, leukocyte function associated mole- tation and Percoll (Pharmacia) gradient cenrtrifugation followed by 
cule-l; IL-l, interleukin-; FITC, fluorescein isothiocyanate. hypotonic lysis of contaminating erythrocytes [16]. The purity of 
0014-5793/95/$9.50 0 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(95)00299-5 
142 i? Horikoshi et al. IFEBS Letters 363 (1995) 141-144 
PBMCs was more than 90%. PBMCs were then suspended in MEM 
containing 1 %FCS before assay. 
2.5. Cell attachment assay 
Semiconfluent cultures of fibroblasts in 96 well microplates (Falcon) 
were treated with 10 U/ml of TNF-a in the presence or absence of 1000 
IU/ml of IFN-8 for 48 h. PBMCs (3 x 105cells/100 ul of MEM) were 
then added to ihe cytokine treated hbroblasts for 36 min. Unatiached 
cells were removed by rinsing three times with PBS. Then attached cells 
were stained with 0.25% (w/v) Rose bengal in PBS for 5 min [17]. After 
washing three times with PBS, dye incorporated into PBMCs was 
eluted with 100 ~1 of PBS : ethanol (I : 1). The absorbance of eluted dye 
was read in a 2-wave length microplate photometer (Corona, Japan) at 
570 nm. Results were presented after the subtraction of absorbance 
values of dye incooporated to fibroblasts. Cell number was directly 
proportional to the absorption of eluted dye [18]. The absorbance of 
dye incorporated into PBMCs adhering to TNF-a-untreated fibro- 
blasts were set as controls. Data were expressed as % increase of con- 
trol. For inhibition assay, cells treated by the same doses of TNF-a and 
IFN-/3 were incubated with lO,@ml of anti-ICAM- MoAb for 30 min. 
The final concentration of sodium azide was O.OOl%, showing no inhib- 
itory effect on cell activity. Then PBMCs were allowed to attach to 
fibroblasts for 30 min. The number of attached cells was calculated in 
the same way for cell attachment assay. 
2.6. Statistical analysis 
All experiments were performed at least three times. Results were 
shown as mean & S.D. Statistical significance of data was analyzed 
using Student’s t-test. 
3. Results 
3.1. Up-regulation of ICAM- by TNF-a 
The effects of TNF-a on the expression of ICAM- of human 
cultured dermal fibroblasts were examined using flow cytom- 
etry. Non-treated human fibroblasts expressed very low levels 
of ICAM-1. When cells were treated with TNF-a for 48 h at 
concentrations of 1, 10, 100, and 1000 U/ml, the expression of 
ICAM- was significantly increased in a dose dependent man- 
ner (Fig. 1) as reported previously [2,9,11]. 
TNF-a 0 1 10 100 1000 
(U /ml) 
Fig. 1. Up-regulation of ICAM- 1 by TNF-(r. The expression of ICAM- 
1 of fibroblasts increased significantly in a dose dependent manner 
compared to that of controls when cells were treated with TNF-a for 
48 h at concentrations of 1, 10, 100, and 1000 U/ml. Data of FACS are 
expressed as log mean fluorescence. All experiments were performed at 
least three times. Results are shown as mean f S.D. *P < 0.01 com- 
pared to TNF-untreated cells. Statistical significance of data was ana- 
lyzed using Student’s t-test. 
TNF-a 0 10 10 10 10 0 
IFN-0 0 0 10 100 1000 1000 
(IV/ml) 
Fig. 2. Effect of IFN-B on TNF-a-induced ICAM- expression. When 
cells were treated with IFN-p at concentrations of 10, 100, and 1000 
IU/ml in the presence of 10 U/ml of TNF-a, the expression of ICAM- 
could be up-regulated significantly above that seen by treatment of 
fibroblasts with TNF-a alone. Each up-regulation of ICAM-I was 
statistically significant and dependent on the dose of IFN;B. The up- 
regulation of ICAM- was not observed by the treatment of 1000 IU/ml 
of IFN-8 alone. Data of FACS are expressed as log mean fluorescence. 
All experiments were performed at least three times. Results are shown 
as mean + S.D. ??*P < 0.05 and ??**P<O.Ol compared to untreated 
cells. Statistical significance of data was analyzed using Student’s t-test. 
3.2. Effect of IFN-8 on TNF-a-induced ICAM- expression 
When cells were treated with IFN-P at concentrations of 10, 
100, and 1000 IU/ml in the presence of 10 IU/ml of TNF-a for 
48 h, the expression of ICAM- could be up-regulated signifi- 
cantly above that seen by treatment of fibroblasts with TNF-a 
alone (Fig. 2). However, the further up-regulation of ICAM- 
was not observed even if the concentrations of TNF-a were 
increased to 100 and 1000 U/ml in the presence of 1000 IU/ml 
of IFN-p (data not shown). The expression of ICAM- was not 
up-regulated by IFN-/I alone at concentrations of 1, 10, 100, 
and 1000 IU/ml (data not shown). 
3.3. Effect of IFN-p on the attachment of PBMCs to 
TNF-a-treatedjibroblasts 
As unstimulated PBMCs expressed LFA-1 [19], we investi- 
gated whether up-regulated ICAM- expression of fibroblasts 
by either IFN-p with TNF-a or TNF-a alone modulated the 
attachment of PBMCs. The number of PBMCs attached to 
fibroblasts in the presence of TNF-a (10 U/ml) increased by 
12% compared to that of controls. More than twice the number 
of cells attached to fibroblasts were noted in the presence of 
IFN-p (1000 IUlml) and TNF-a (10 U/ml). 
These increases in the number of attached cells were statisti- 
cally significant and dependent on the dose of IFN-P (data at 
doses of 10 and 100 IU/ml of IFN-#I not shown). Furthermore 
it was noted that there was a tendency for attachment of 
PBMCs to either TNF-a alone or TNF-a with IFN-B-treated 
fibroblasts were inhibited by anti-ICAM- MoAb (Fig. 3). 
4. Discussion 
TNF-a has been shown to be a growth factor of human 
non-transformed fibroblasts [20,21]. We previously reported 
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Fig. 3. Inhibitory effect of ICAM- MoAb on the attachment of PBMC 
to TNF-a and/or IFN-/? fibroblasts. The number of PBMCs adhered 
to TNF-a (10 U/ml)-treated fibroblasts increased by 12% compared to 
that of controls. The treatment with 1000 IU/ml of IFN-/l and 10 U/ml 
of TNF-a resulted in a more than twofold increase in the number of 
cells adhered to fibroblasts. This increase in the number of adhered cells 
was statistically significant (P < 0.051 compared to TNF-treated cells). 
Furthermore it was noted that there was a tendency that attachments 
of PBMCs to either TNF-a alone or TNF-a with IFN-b-treated fibro- 
blasts were inhibited by anti-ICAM- MoAb. P values were, however, 
more than 0.05. Data were expressed as % increase of control. 
that TNF-a preferentially induced the expression of a2pl inte- 
grins of human skin fibroblasts in a dose- and time-dependent 
manner and increased the number of cells attached to type I 
collagen [15]. TNF-a was assumed to regulate the attachment 
and migration of fibroblasts in the processes of wound healing. 
A number of cytokines have been identified and some of their 
effects are known to regulate cell adhesion molecules. However, 
cytokines can have positive and negative biological effects and 
form a complex network in vivo [18,22]. For examples, in vitro, 
IL-4 decreases the IFN-y-induced ICAM- expression of an 
endothelial cell line, whereas IL-4 alone has no effect on 
ICAM- expression. At the same time, IL4 could not up-regu- 
late TNF-a-induced ICAM- expression [23]. Recently, it was 
reported that ICAM- is highly expressed on melanoma cells 
and its expression correlates with increased risk of metestasis 
[24,25]. In Japan, human IFN-/? (3-12 x lo6 IU) has been 
widely accepted as an effective treatment and administered to 
the adjacent normal skin of the melanoma lesion [26]. We pre- 
viously reported that IFN-p possessed anti-proliferative and 
anti-invasive effects on melanoma cells in vitro [27]. However, 
the skin immune and inflammatory responses exerted by locally 
administered IFN-/3 have not been fully explored. In the dermal 
tissues near the metastatic melanoma cells, mononuclear cell 
infiltration is rarely seen. This is appreciated to be due to the 
escape of melanoma cells from the immune surveillance system. 
After the local administration of IFN-B, however, infiltration 
of mononuclear cells are often observed near melanoma cells 
in the dermis. Moreover, the augmentation of ICAM- expres- 
sion was not observed on melanoma cells but rather noted on 
dermal fibroblasts in the surrounding tissues in vivo (data not 
shown) [28]. The mechanism explaining the recruitment of infil- 
trating mononuclear cells has not been explained yet. Therefore 
we investigated the effects of IFN-/S on the expression 
of ICAM- in cultured human dermal fibroblasts using flow 
cytometry. In our results, IFN-p significantly increased TNF- 
a- induced ICAM- expression in a dose-dependent manner, 
although IFN-/J alone, even at concentration of 1000 IUlml, did 
not up-regulate the expression of ICAM-1. It is known that 
significant concentrations of IFN-/3 are not detectable when it 
is locally administered. However, in lesional lymph nodes, high 
concentrations (200 to 1000 II-J/g of wet tissue) of IFN-/3 were 
verified [29]. Thus the concentrations of IFN-/l we emplyed in 
our experiments, ranging from 10 to 1000 IUlml, was assumed 
to be compatible with the in vivo concentration. It is possible 
to assume that IFN-/J regulates ICAM- expression in a coop- 
erative way with TNF-a, resulting in the attachment of PBMCs 
into the site of inflammation and probably exerting an anti- 
tumoral effect. Further studies will be necessary to elucidate the 
function of PBMCs following the attachment to the fibroblasts 
through the interaction between ICAM- and LFA-1. 
Investigations of a cytokine network in regulating ICAM- 
expression on dermal fibroblasts will lead to an understanding 
the mechanisms not only of various skin inflammatory diseases 
but also skin immune responses. 
Acknowledgements: The late Makoto Takahashi, MD, PhD, Professor 
and Chairman, Department of Dermatology, School of Medicine, Sap- 
poro Medical University, and the late D. Martin Carter, MD, PhD, 
Professor & Senior physician, Laboratory for Investigative Dermatol- 
ogy, The Rockefeller University, gave encouragement and assisted in 
a critical reading of this manuscript. This work was supported in part 
by Grant 04670644 (T.H) from the Ministry of Education, Science and 
Culture of Japan. 
References 
[1] Rothlein, R., Dustin, M.L., Marlin, S.D. and Springer, T.A. 
(1986) J. Immunol. 137, 1270-1274. 
[2] Dustin, M.L., Rothlein, R., Bhan, A.K., Dinarello, C.A. and 
Springer, T.A. (1986) J. Immunol. 137, 2455254. 
[3] Marlin, S.D. and Springer, T.A. (1987) Cell 51, 813-819. 
[4] Stauton, D.E., Marlin, S.D., Stratowa, C., Dustin, M.L. and 
Springer, T.A. (1988) Cell 52, 9255933. 
[5] Sanchez-Madrid, F., Nagy, J.A., Robbins, E., Simon, P. and 
Springer, T.A. (1983) J. Exp. Med. 158, 178551803. 
[6] Nickoloff, B.J., Griffiths, C.E.M. and Barker, J.N.W.N. (1990) 
J. Invest. Dermatol. 94, 151S157S. 
[7] Dustin, M.L., Singer, K.H., Tuck, D.T. and Springer, T.A. (1988) 
J. Exp. Med. 267, 132331340. 
[8] Kupper, T.S. (1989) Arch. Dermatol. 125, 140661412. 
[9] Rothlein, R., Czajkowski, M., O’Neill, M.M., Marlin, SD., 
Mainolfi, E. and Merluzzi, V.J. (1988) J. Immunol. 141, 16655 
1669. 
[lo] Marlor, C.W., Webb, D.L., Bombara, M.P., Greve, J.M. and 
Blue, M.L. (1992) Am. J. Pathol. 140, 105551060. 
[ll] Piela-Smith, T H., Broketa, G., Hand, A. and Korn, J.H. (1992) 
J. Immunol. 48, 1375-1381. 
[12] Isaacs, A. and Lindenmann, J. (1957) Proc. R. Sot. Lond. B. 147, 
2588267. 
[13] Gresser, I. (1990) J. Invest. Dermatol. 95, 66S-71s. 
[14] Sehgal, P.B., Dobberstein, B. and Tamm, I. (1977) Proc. Natl. 
Acad. Sci. USA 74, 3409-3413. 
[15] Ezoe, K. and Horikoshi, T. (1993) Biochem. Biophys. Res. Com- 
mun. 192, 281-287. 
[16] Gamble, J.R. and Vadas, M.A., (1988) J. immunol. Methods. 
109,1755184. 
[17] Shock, A., Rabe, K.F., Dent, G., Chambers, R.C., Gray, A.J., 
Chung, K.F., Barnes, P.J. and Laurent, G.J. (1991) Clin. Exp. 
Immunol. 86, 185-190. 
[18] Elias, J.A., Freundlich, B., Kern, J.A. and Rosenbloom, J. (1990) 
Chest. 97, 143991445. 
144 7: Horikoshi et al. IFEBS Letters 363 (1995) 141-144 
[19] Springer, T.A., Dustin, M.L., Kishimoto, T.K. and Marlin, S.D. 
(1987) Annu. Rev. Immunol. 5, 223-52 
[20] Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S., Palladino 
Jr., M.A. and Shepard, H.. (1985) Science 236 9433945. 
I211 Vilcek, J.. Palombella. V.J.. Destefano. D.H.. Swenson. C.. Fein- . 1  
man, R., Hirai, M. and Tsujimoto, Ml (1986) J. Exp. ‘Med. 163, 
632-643. 
[22] Kohase, M., May, L.T., Tamm, I., Vilcek, J. and Sehgal, P.B. 
(1987) Mol. Cell Biol. 7, 2733280. 
[23] Renkonen, R., Mattila, P., Majuri, M.L., Paavonen, T. and Silven- 
noinen, 0. (1992) Stand. J. Immunol. 35, 5255530. 
[24] Natali, P.G., Nictra, M.R., Cava-liere, R., Bigotti, A., Romano, 
G., Temponi, M. and Ferrone, S. (1990) Cancer Res. 50, 1271- 
1278. 
[25] Johanson, J.P., Stade, B.G., Holzmann, B., Schwale, W. and 
Riethmuller, G. (1989) Proc. Natl. Acad. Sci. USA 86.641- 
644. 
[26] Yamamoto, A., Sumi, A. and Mori, S. (1988) Biotherapy 2, 1733 
177 (in Japanese). 
[27] Fukuzawa, K. and Horikoshi, T. (1992) Br. J. Dermatol, 126, 
324-330. 
[28] Eguchi, H., Horikoshi, T., Takahashi, M., Imai, K., Tujisaki, M. 
and Kageshita, T. (1992) Jpn. J. Dermatol. 102, 8077814 (in Japa- 
nese). 
[29] Ishihara K. and Ichikawa H. (1988) Biotherapy 2, 1688172 (in 
Japanese). 
